Asset Details
Do you wish to reserve the book?
Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves’ disease and papillary thyroid cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves’ disease and papillary thyroid cancer
Do you wish to request the book?
Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves’ disease and papillary thyroid cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves’ disease and papillary thyroid cancer
2025
Overview
Graves’ disease has been associated with increased tumor aggressiveness in differentiated thyroid carcinoma, however, its correlation with thyroid stimulating immunoglobulin (TSI) remains unclear.
A tri-institutional retrospective review of 96 thyroidectomy patients with Graves’ disease and papillary thyroid carcinoma (PTC) was performed (2002–2020). Clinicopathologic features and recurrence were compared based on TSI level.
ATA risk stratification distribution was low (72.9 %), intermediate (14.6 %), and high (12.5 %). Recurrence rate was 11.5 % with median follow-up of 3.2 years. TSI was not associated with high-risk clinicopathologic features at its 50 % and 75 % quartiles. There was no difference in median TSI between patients with recurrence versus no recurrence [212 (IQR 98–361) vs. 327 (IQR 152–461), p = 0.148]. TSI was not associated with recurrence on univariable Cox regression, even when excluding microcarcinomas.
In this majority low-risk PTC cohort with concomitant Graves’ disease, TSI level is not associated with aggressive clinicopathologic features or recurrence.
[Display omitted]
•Graves' disease has been associated with tumor aggressiveness in thyroid cancer.•Thyroid stimulating immunoglobulin (TSI) can stimulate thyroid cell growth.•TSI level is not associated with aggressive tumor pathologic features.•Patients with high TSI are not at higher risk for thyroid cancer recurrence.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Adult
/ Aged
/ Cancer
/ Female
/ Graves Disease - complications
/ Humans
/ Immunoglobulins, Thyroid-Stimulating - blood
/ Iodine
/ Male
/ Neoplasm Recurrence, Local - epidemiology
/ Risk
/ Thyroid
/ Thyroid Cancer, Papillary - blood
/ Thyroid Cancer, Papillary - complications
/ Thyroid Cancer, Papillary - pathology
/ Thyroid Cancer, Papillary - surgery
/ Thyroid Neoplasms - complications
/ Thyroid Neoplasms - pathology
/ Thyroid stimulating immunoglobulin
/ Tumors
We currently cannot retrieve any items related to this title. Kindly check back at a later time.